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Abstract
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the
nuclear receptor peroxisome proliferator‐activated receptor γ (PPARγ) and have
been investigated in several clinical trials for their potential in treating non‐alcoholic
fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH). PPARγ has
specialized roles in distinct tissues and cell types, and although the primary function
of PPARγ is in adipose tissue, where the highest expression levels are observed,
hepatic expression levels of PPARγ are significantly increased in patients with
NAFLD. Thus, NAFLD patients receiving treatment with PPARγ agonists might
have a liver response apart from the one in adipose tissue. Owing to the different
roles of PPARγ, new treatment strategies include development of compounds har-
nessing the beneficial effects of PPARγ while restricting PPARγ unwanted effects
such as adipogenesis resulting in weight gain. Furthermore, dual or pan agonists tar-
geting two or more of the PPARs have shown promising results in pre‐clinical
research and some are currently proceeding to clinical trials. This MiniReview
explores adipose‐ and liver‐specific actions of PPARγ, and how this knowledge
may contribute in the search for new treatment modalities in NAFLD/NASH.
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1 | INTRODUCTION
The global prevalence of non‐alcoholic fatty liver disease
(NAFLD) has reached 25% of the adult population and con-
tinues to rise.1 The increasing disease frequency reflects the
high energy intake and sedentary lifestyle characteristics of
modern day living, fuelling a cluster of detrimental lifestyle‐
associated diseases including NAFLD.2 NAFLD is closely
linked to diet‐induced dyslipidaemia, metabolic co‐morbidi-
ties such as dysregulated glucose and lipid metabolism in
turn promoting obesity, type 2 diabetes and cardiovascular
diseases.2,3 The term NAFLD covers a wide range of hep-
atic disease states ranging from bland steatosis to non‐alco-
holic steatohepatitis (NASH) with developing hepatic
fibrosis, which may progress and ultimately lead to cirrhosis
and increased risk of hepatocellular carcinoma 2,4. Although
NAFLD and NASH represent a major burden to the patient
and the supporting health system, there is currently no
approved pharmacotherapy targeting the disease, emphasiz-
ing the current need for novel intervention strategies.
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In the quest of discovering relevant treatment targets,
peroxisome proliferator‐activated receptor γ (PPARγ) and
the synthetic PPARγ agonists thiazolidinediones (TZD; e.g.
rosiglitazone and pioglitazone) have been the subject of
increasing attention.5,6 Large randomized controlled clinical
trials have reported that both rosiglitazone and pioglitazone
improve NAFLD‐related hepatic steatosis and, in the case
of pioglitazone, also hepatic inflammation and to a lesser
extent fibrosis (Table 1).7–13 However, TZD treatment has
also been associated with weight gain and fluid retention,
limiting its application and potentially reducing patient
compliance.7–10 This review elaborates on the role of
PPARγ in adipose and liver tissues, addressing how
PPARγ expression and/or activation may affect different
cell types and signalling pathways, and how this may be
exploited in a therapeutic setting.
2 | PPARγ IN ADIPOSE TISSUE
PPARγ is a transcription factor and part of a nuclear recep-
tor family comprised of PPARγ, PPARα and PPARδ (also
known as PPARβ).6 Expression is highest in adipocytes,
where PPARγ functions as an inducer of adipocyte differ-
entiation.14,15 TZDs have significant anti‐diabetic properties
in vivo, mediated—at least in part—through increased insu-
lin sensitivity and the selective activation of PPARγ in adi-
pose tissue.16,17 By promoting adipose tissue formation,
PPARγ paradoxically acts as an insulin sensitizer, even
though excess adiposity and obesity is commonly associ-
ated with diabetes and insulin resistance.18 This apparent
discrepancy involves the generation of metabolically dys-
functional adipocytes during chronic dyslipidaemia, often
accompanied by obesity. Dysfunctional adipose tissue is
characterized by hypertrophic tumour necrosis factor α
(TNFα) producing adipocytes with enhanced rates of lipol-
ysis due to insulin resistance.19 The enhanced lipolysis
increases the release of free fatty acids (FFAs), which may
proceed to be ectopically stored, for example, in the liver,
leading to steatosis and lipotoxicity, in turn progressing to
NASH and cirrhosis.4,20 PPARγ activation mitigates this
vicious circle by promoting the formation of insulin‐sensi-
tive adipose tissue dominated by small adipocytes, which
can act as a reservoir for excess FFAs thereby potentially
preventing lipotoxicity in other tissues and organs (Fig-
ure 1).15,19
In adipocytes, PPARγ modulates an array of target
genes involved in lipid uptake and storage, inflammatory
cytokine production and the release of insulin‐sensitizing
adipokines.15 Adipocyte lipid uptake is regulated in part by
cluster of differentiation 36 (also known as fatty acid
translocase), adipocyte protein 2 and lipoprotein lipase, all
of which are up‐regulated by PPARγ in response to TZD
treatment (Figure 1).21–23 Following uptake of FFAs,
PPARγ activation up‐regulates phosphoenolpyruvate car-
boxykinase, which provides the glycerol backbone for
esterification and storage of triglycerides, promoting forma-
tion of intracellular lipid vesicles and, consequently, protec-
tion from FFA‐induced lipotoxicity (Figure 1).24
Adipose tissue not only serves as a passive storage site
for lipids but also as a recognized endocrine tissue,
enabling local and systemic signalling and tissue crosstalk,
for example, by the release of cytokines such as TNFα and
adiponectin.25 In the liver, circulating adiponectin activates
AMP‐activated protein kinase and subsequently induces
fatty acid oxidation while lowering gluconeogenesis and
insulin resistance (Figure 1).26 Expectedly, treatment of ob/
ob mice with recombinant adiponectin improved hepatic
steatosis and decreased hepatic TNFα expression.27 In
accordance, full length adiponectin ameliorated hepatic
fibrosis in mice fed a NAFLD promoting methionine‐ and
choline‐deficient (MCD) diet, supporting a direct effect of
adiponectin on key components of progressive NAFLD.28
Thus, adiponectin would seem a relevant target point in
the treatment of NAFLD; however, the extensive post‐
translational modifications and a large range in circulating
normal physiological levels (0.5‐30 µg/mL plasma) have so
far limited the applicability of adiponectin as a commer-
cially available therapeutic tool.27,29,30 Consequently,
induction of adiponectin expression and release through
up‐regulators such as TZDs remain an option to harness
the beneficial effects of this adipokine.29,30 Randomized,
placebo‐controlled clinical trials9,13 as well as experimental
data from a systematic review30 report an increase of adi-
ponectin levels in response to TZD treatment in parallel
with an improvement of hepatic steatosis. This suggests
adiponectin as an important factor in TZD‐mediated
effects. In a study using adiponectin null mice, TZDs were
found to be dependent on adiponectin in improving glu-
cose tolerance, providing evidence of adiponectin as a key
player in TZD treatment.31 Whether adiponectin depen-
dence translates to human and liver related TZD effects
has currently not been investigated, but would provide
much needed information on the mechanisms behind the
effects of TZD treatment. In addition to providing benefi-
cial effects by inducing adiponectin levels, PPARγ activa-
tion also reduces the expression of the inflammatory
cytokine TNFα in adipose tissue, which may improve insu-
lin sensitivity by inhibiting TNFα‐induced insulin resis-
tance.15,19
Thus, activation of PPARγ increases adipose tissue fat
storage capacity as well as systemic and local insulin sensi-
tivity. However, these benefits come at the expense of
increased adiposity, which in itself may increase the risk of
debilitating co‐morbidities and reduce patient compliance,
collectively supporting the need for refined pharmacologi-
cal targeting of PPARγ.
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3 | PPARγ IN THE LIVER
Studies in lipoatrophic AZIP mice have shown that in the
absence of adipose tissue, the liver is the primary target of
TZDs.16 In the liver, PPARγ regulates a multitude of pro-
cesses in hepatocytes, liver resident macrophages (Kupffer
cells) and hepatic stellate cells (HSCs).32–37 The latter two
are pivotal in the progression of hepatic inflammation and
the development of fibrosis, hence in NAFLD progression
and subsequently in determining patient outcome.2,4 A
putative role in disease progression is supported by the
finding of increased hepatic PPARγ expression in NAFLD
patients, linking PPARγ to the pathogenesis of NAFLD.38
3.1 | PPARγ in hepatocytes
In hepatocytes, PPARγ is a regulator of lipid metabolism,
targeting genes involved in de novo lipogenesis (DNL) and
FFA import (Figure 2). In response to a high‐fat diet
(HFD), adipose tissue becomes dysfunctional promoting
lipolysis and subsequently hyperlipidaemia.20 This can
cause the liver to act as a secondary reserve for the excess
lipid load, inducing the expression of adipogenic genes
including PPARγ, mediating an adipogenic transformation
of hepatocytes.39–41 In hepatocytes, PPARγ promotes adi-
pocyte protein 2 and cluster of differentiation 36‐mediated
FFA uptake and induces the DNL enzymes’ fatty acid syn-
thase and acetyl‐CoA carboxylase 1, facilitating an increase
in hepatic triglycerides (Figure 2).39,40,42,43 Thus, the hep-
atic effects of PPARγ appear to be steatogenic, promoting
the deposition of intracellular lipids. Indeed, mice with
hepatocyte‐specific knockout of PPARγ showed a signifi-
cant reduction in hepatic lipid vacuoles, as well as down‐
regulation of DNL activators: sterol regulatory element
binding protein 1c and acetyl‐CoA carboxylase 1, fatty acid
importer cluster of differentiation 36 and storage enzyme
phosphoenolpyruvate carboxykinase, in response to a HFD
compared with wild‐type controls (Table 2).33 Despite
reducing hepatic steatosis, hepatocyte‐specific PPARγ abla-
tion in lipoatrophic AZIP mice caused a 33% increase in
muscle triglyceride content and induced insulin resistance,
emphasizing that PPARγ is not only a key factor in hepatic
lipid homeostasis, but also exerts significant effects in reg-
ulating lipid deposition and cellular metabolism in addi-
tional tissues.16 Furthermore, liver‐specific PPARγ
knockout in ob/ob mice significantly increased serum FFA
levels by almost 60%, while reducing liver triglyceride con-
tents compared with control mice.43 Consequently,
decreased hepatic lipid content follows the disruption of
hepatocyte PPARγ, but comes at the expense of excess
lipid delivery to other tissues, such as striated muscles.
This augments insulin resistance (which has been reported
in some studies of PPARγ knockout mice16,43) and, subse-
quently, the development of type 2 diabetes, and may
undermine an—at first glance beneficial—anti‐steatogenic
effect of PPARγ inhibition in hepatocytes.
Rosiglitazone treatment in obese ob/ob and the obese/di-
abetic KKAγ mouse model (KK mouse strain crossed with
mice carrying the yellow obese gene Aγ44) increased hep-
atic lipid accumulation, again substantiating the steatogenic
role of hepatocyte PPARγ agonism.43,45 In line with these
findings, the expected outcome of the increased hepatic
PPARγ expression reported for NAFLD patients would be
hepatocyte activation of DNL and adipogenic gene expres-
sion subsequently resulting in aggravated steatosis.38,41
Yet, clinical trials show significant reduction of hepatic
steatosis in NAFLD patients treated with the PPARγ ago-
nists rosiglitazone and pioglitazone (Table 1).7–9,46 This
alleviation is likely caused by effects in the adipose tissue,
where PPARγ activation supports the formation of healthy
adipose tissue thereby preventing shunting of excess lipids
to the liver and the formation of dysfunctional
FIGURE 1 PPARγ‐mediated effects in adipocytes. In adipocytes,
PPARγ regulates the expression of genes controlling FFA uptake,
storage and adipose tissue endocrine function. PPARγ activation leads
to increased expression of CD36, Ap2 and LPL which are all
involved in the enhanced transport and uptake of free fatty acids
across the cell membrane. The increased expression of PEPCK exerts
excessive production of triglycerides from the incoming FFAs,
leading to intracellular fat deposition. PPARγ also induces increased
adiponectin expression, mediating higher amounts of circulating
adiponectin and facilitating tissue crosstalk. Circulating adiponectin
will bind to receptors in the liver initiating signalling cascades leading
to increased β‐oxidation, decreased gluconeogenesis and less insulin
resistant hepatic tissue. Lastly, the lower TNFα production will
prevent recruitment and activation of immune cells, adipose tissue
dysfunction and systemic low‐grade inflammation. Ap2, Adipocyte
Protein 2; CD36, Cluster of Differentiation 36; FFA, Free Fatty
Acids; LPL, Lipoprotein Lipase; PEPCK, Phosphoenolpyruvate
Carboxykinase; TNFα, Tumour Necrosis Factor α. Blue arrows:
Increase, grey arrows: Decrease
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adipocytes.6,15 An increased formation of adipose tissue is
supported by the observed weight gain in TZD‐treated
NAFLD patients.7,9,10 Although patients with NAFLD dis-
play increased levels of liver PPARγ, the specific events
triggering this up‐regulation during disease progression
have not yet been identified.38 PPARγ might be up‐regu-
lated in response to lipid accumulation in hepatocytes, or
PPARγ could be up‐regulated in response to stimuli prior
FIGURE 2 PPARy‐mediated effects in the liver. PPARγ serves distinct functions in the various cell types of the liver. In hepatocytes,
PPARy has a steatogenic role, mediating expression of adipogenic genes such as Ap2 and CD36 inducing increased FFA uptake. The
simultaneous induction of FAS and ACC1 promotes intracellular TG accumulation. In liver macrophages, both Kupffer cells and infiltrating
monocytes, PPARγ promotes the alternatively activated (M2) macrophage phenotype, while inhibiting activation of the classically activated (M1)
macrophage. This decreases the release of inflammatory cytokines (EG TNFα and MCP1) and growth factors (TGFβ), resulting in reduced
inflammation, and hepatic stellate cell activation in turn attenuating fibrosis. Finally, PPARy is associated with the quiescent phenotype of HSC
limiting activation of HSC and subsequently fibrosis. ACC1, Acetyl‐CoA Carboxylase 1; Ap2, Adipocyte Protein 2; CD36, Cluster of
Differentiation 36; DNL, De Novo Lipogenesis; FAS, Fatty Acid Synthase; FFA, Free Fatty Acid; Green text/“+”, increased; HSC, Hepatic
stellate cell; MCP1, Monocyte chemoattractant protein 1 (CCL2); Red text/“−”, decreased; TG, Triglyceride; TGFβ, Transforming Growth Factor
β; TNFα, Tumour Necrosis Factor α. Grey arrows: Decreased pathway induction
TABLE 2 Pre‐clinical mouse models of cell‐specific PPARγ knockout
Genotype
Model
of
injury
Altered hepatic
gene expression
Liver
features Metabolic features Compound Compound effect
PPARγΔHep33 HFD β‐ox↓
DNL↓
Import↓
Steatosis↓ Improved glucose
clearance
Rosiglitazone Loss of steatogenic effect
compared with WTb
PPARγΔHep
AZIPa16
None Non‐significant
findings
Steatosis↓ Hyperlipidaemia, impaired
muscle insulin sensitivity
Rosiglitazone Loss of steatogenic effect
compared with AZIP WT
PPARγΔHep
ob/ob43
None DNL↓ Steatosis↓ Hyperlipidaemia
Impaired muscle insulin
sensitivity
Rosiglitazone Loss of steatogenic effects
compared with ob/ob WT
PPARγΔMac34 CCL4 Inflammatory↑
Fibrotic ↑
Inflammation↑
Fibrosis↑
ND Rosiglitazone + LPS Increased expression of
pro‐inflammatory M1
markersb
PPARγΔHSCc34 CCL4 Fibrotic ↑ Fibrosis↑ ND Rosiglitazone ND
Δ: PPARγ deletion in specific cell type; DNL, de novo lipogenesis; Hep, hepatocyte; HFD, high‐fat diet; HSC, hepatic stellate cell; IR, insulin resistance; Mac,
macrophages; ND, no data; WT, wild‐type; β‐ox, β‐oxidation.
aMice did not develop adipose tissue.
bOnly tested in precision‐cut liver slices and primary hepatocyte cultures.
cHSC‐specific PPARγ disruption was performed under control of the aP2 promoter, and aP2 is not HSC specific but also expressed in adipocytes70 and Kupffer
cells.
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to the lipid build‐up. As PPARγ induces the expression of
genes involved in lipid uptake and storage, an up‐regula-
tion of PPARγ prior to steatosis could place PPARγ as a
causal factor of hepatic lipid accumulation in NAFLD
patients. In mice subjected to HFD‐induced NAFLD,
PPARγ was up‐regulated as early as 2 weeks after initiat-
ing the dietary regime, preceding development of obesity
and insulin resistance.47 At this time‐point, HFD‐fed mice
had already developed steatosis, but as PPARγ levels were
not measured earlier, a time‐dependent up‐regulation prior
to the onset of hepatic histopathological lesions could not
be assessed. The finding that adenovirus‐induced hepatic
PPARγ overexpression led to hepatocyte lipid accumulation
(steatosis) even in the absence of a dyslipidaemic diet,43
supports a link between PPARγ expression and induced
liver steatosis.
3.2 | PPARγ in liver macrophages and
Kupffer cells
In response to a hepatic insult, such as increased lipid load,
resident hepatic macrophages (Kupffer cells) are activated
(Figure 2). Upon activation, Kupffer cells release inflamma-
tory cytokines leading to the recruitment of additional
immune cells, fuelling the inflammatory cascade and NASH
progression.48 Macrophages have been broadly classified as
classically activated inflammatory (M1) or alternatively acti-
vated anti‐inflammatory (M2). M1 macrophages express
pro‐inflammatory cytokines such as TNFα, interleukin‐1
(IL‐1β), IL‐8 and metabolize arginine to nitric oxide, which
can be further processed into reactive nitrogen species. M2
macrophages express anti‐inflammatory cytokines (eg IL‐10)
and growth factors such as TGFβ and metabolize arginine
to ornithine and urea, providing precursors for amino acid
and collagen synthesis important for tissue remodelling.48,49
A current view on macrophage polarization is more nuanced
and suggests a “spectrum model” encompassing a wider
range of activation states, reflecting the many different stim-
uli and subsequent response characteristics.50,51 However,
for the simplicity of this MiniReview, and in relation to the
terminology of the papers included, we will refer to the M1
and M2 macrophage states. In morbidly obese patients,
markers of liver M2 macrophages were inversely correlated
with the degree of liver steatosis, suggesting a “macro-
phage‐switch” away from the anti‐inflammatory M2 pheno-
type as an indicator of NAFLD disease stage, at least in this
subgroup of patients.52 However, the study did not disclose
a putative link between M2 markers and degree of hepatic
inflammation and fibrosis, leaving the predictive and
putative therapeutic potential of the M1:M2 findings to be
further explored.
The role of macrophage (including Kupffer cell) polar-
ization in NAFLD has been addressed in studies with
C57Bl/6 mice. This mouse strain does not support the com-
plete maturation of the M2 phenotype, resulting in an
enhanced M1 polarization and subsequent increased NASH
severity, compared with Balb/c counterparts, which do not
exhibit this “M1‐bias”.35,53,54 In Balb/c mice, bone mar-
row‐derived macrophage‐specific PPARγ deletion inhibited
maturation of M2 macrophages and promoted insulin resis-
tance as well as diet‐induced obesity.35 Furthermore, CCL4
‐induced liver injury caused increased hepatic expression of
M1 inflammatory cytokines (TNFα and IL‐1β) and exacer-
bated fibrosis in mice with Kupffer cell‐specific PPARγ
deficiency compared with wild‐type controls (Table 2).34
This indicates that loss of macrophage PPARγ induces M1
polarization and enhances liver injury. Conversely, PPARγ
activation might improve NAFLD/NASH by negating M1
polarization and the ensuing inflammatory cascade, instead
promoting M2 activation (Figure 2). Accordingly, a recent
study found that PPARγ induction by rosiglitazone
decreased the number of M1 Kupffer cells in the liver,
attenuating the inflammatory response as well as steatosis
in a diet‐induced murine NAFLD model.32 However,
whether rosiglitazone reduced the number of M1 Kupffer
cells directly or whether the effect was indirectly mediated
through the decreased degree of steatosis was not assessed.
Collectively, these studies suggest a central role of
PPARγ in NAFLD‐associated hepatic inflammation, by
promoting the activation of M2 macrophages while reduc-
ing the number of M1 macrophages, thereby, alleviating
inflammation and preventing disease progression.
3.3 | PPARγ function in hepatic stellate cells
Hepatic stellate cells are characterized by enhanced α
smooth muscle actin, extracellular matrix production and
play a central role in the fibrotic deposition in NAFLD.55
During NAFLD progression, growth factors such as TGFβ
induce HSCs to switch from a PPARγ expressing quiescent
phenotype to an activated phenotype with decreased
PPARγ expression (Figure 2).55–57 Activated hepatic stel-
late cells also produce tissue inhibitors of metallopro-
teinases (TIMPs), which inhibit matrix degradation,
promoting fibrosis.56
Pioglitazone treatment prevented hepatic fibrosis and
reduced the expression of the pro‐fibrotic TIMP‐1 and
TIMP‐2 genes in rats subjected to a NAFLD‐inducing, cho-
line‐deficient L‐amino acid‐defined (CDAA) diet.58 In mice
subjected to an MCD diet, overexpression of PPARγ
reversed hepatic fibrosis and reduced the expression of α
smooth muscle actin, TIMP‐1 and TIMP‐2 indicating that
PPARγ directly reduced liver fibrosis.37 In line with these
findings, HSC‐specific ablation of PPARγ aggravated
CCL4‐induced liver fibrosis and increased α smooth muscle
actin expression (Table 2).34 Collectively, these findings
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link increased PPARγ activation/expression to reductions in
hepatic fibrosis; however, treatment effectiveness may
depend on time of intervention and disease severity.
Accordingly, pioglitazone only ameliorated hepatic fibrosis
when administered in rats with moderate pericentrilobular
fibrosis, whereas treatment had no effect in animals with
severe bridging fibrosis.59 This could be explained by a
decrease in PPARγ expression concomitant with HSC acti-
vation, reducing TZD effects by diminishing target avail-
ability.57,59 While clinical trials have suggested anti‐
steatogenic and anti‐inflammatory actions of pioglitazone,
and to a lesser degree rosiglitazone, the effects on fibrosis
have been less clear (Table 1). A recent meta‐analysis of
TZD effects from eight randomized, controlled trials
(n = 516) on NASH‐associated liver fibrosis found piogli-
tazone to significantly improve fibrosis, particularly
advanced fibrosis (stage F3‐F4 [bridging fibrosis and cir-
rhosis] to stage F0‐F2 [no fibrosis to mild perisinusoidal/
periportal fibrosis]), whereas this was not the case for
rosiglitazone.11 TZDs may impose additional effects, for
example, by binding alternative targets such as the mito-
chondrial pyruvate carrier.60 Inhibition of the mitochondrial
pyruvate carrier by a next‐generation TZD (MSDC‐0602)
reversed hepatic fibrosis in vivo in mice with diet‐induced
NASH, supporting the mitochondria pyruvate carrier as a
relevant treatment target.61 Pioglitazone is generally used at
a considerably higher dosage than rosiglitazone (30‐45 mg
and 4‐8 mg, respectively),8–10,62 and additional target bind-
ing could be speculated to be a contributing factor to the
superior clinical effect of pioglitazone on NAFLD‐associ-
ated end‐points, compared to other TZDs such as rosiglita-
zone.63
4 | EMERGING STRATEGIES TO
TARGET PPARγ IN THE
TREATMENT OF NAFLD
Assessing the different roles of PPARγ in the liver has
unveiled several potential therapeutic targets. Compounds
targeting PPARγ with higher tissue, cell or pathway speci-
ficity could reduce side effects (such as the unwanted
weight gain reported for TZD treatment) and might prove
superior in treating the multifactorial pathogenesis of
NAFLD.
In healthy individuals, DNL only contributes to ~5% of
the total intrahepatic triglycerides; however, in NAFLD
patients, this number increases to 15%‐23%, indicating an
up‐regulation of DNL, and also suggesting that the major-
ity of intrahepatic triglycerides in NAFLD patients origi-
nate from reduced secretion and/or increased uptake of free
fatty acids.20,64 The latter is in agreement with increased
lipolysis of adipose tissue often seen in individuals suffer-
ing from obesity and insulin resistance.20 PPARγ in
adipose tissue provides an attractive therapeutic target by
decreasing FFA release and ameliorating hepatic steatosis
indirectly by diminishing hepatic lipid uptake. However,
the resulting weight gain—averaging around 2.5 kg in
long‐term TZD treatment—is a major drawback which
potentially reduces compliance and applicability.9 Assess-
ment of post‐translational PPARγ modifications has
revealed a cyclin‐dependent kinase 5 (CdK5) as a potential
drug‐target.65 Cdk5 is expressed in adipose tissue in
response to inflammatory cytokines and a HFD, and phos-
phorylates Ser273 on PPARγ leading to aberrant gene
expression and insulin resistance.65 Rosiglitazone reduced
Cdk5‐mediated phosphorylation of PPARγ in obese indi-
viduals and mediated an improvement in insulin sensitiv-
ity.65 Compared with rosiglitazone, SR1664, a novel small‐
molecule compound, blocked Cdk5‐induced PPARγ phos-
phorylation and had anti‐diabetic effects, despite showing a
limited degree of classical PPARγ agonism, as SR1664 did
not promote adipocyte differentiation or expression of adi-
pogenic genes in the investigated mice.66 Whether Cdk5‐
mediated phosphorylation affects PPARγ‐mediated adi-
pogenic gene expression in hepatocytes has not yet been
investigated. However, if this is the case, inhibiting Cdk5‐
mediated phosphorylation could provide a way to block or
limit an unwanted adipogenic aspect of hepatic PPARγ
action, without compromising the beneficial effects of
PPARγ in HSCs and macrophages.
In contrast to PPARγ which promotes hepatic DNL,
other members of the PPAR family, PPARα and PPARδ,
induce fatty acid oxidation hereby enhancing lipid catabo-
lism.6 Exploiting the positive effects of PPARγ while limit-
ing adverse effects by targeting other PPARs has paved the
road for the development of a new group of dual and pan
agonists, targeting two and three PPARs, respectively. Gli-
tazars constitute a novel group of dual agonists targeting
both PPARγ and PPARα.6 Of these, saroglitazar has shown
promising results in pre‐clinical models, reversing CCL4‐in-
duced hepatic fibrosis and NASH caused by a CDAA diet
in mice.67 Specifically, saroglitazar improved steatosis,
hepatocellular ballooning, lobular inflammation and fibrosis
(scored collectively) by 78% whereas pioglitazone showed
22% and fenofibrate (a PPARα agonist) a 54% improve-
ment, all compared with vehicle.67 Saroglitazar is currently
approved for the treatment of diabetic hypertriglyceri-
daemia and dyslipidaemia in India,67,68 and a phase 3 clini-
cal trial comparing saroglitazar and pioglitazone treatment
in NAFLD patients is currently ongoing (ClinicalTrials.gov
identifier: NCT02265276). The pan agonist IVA337 has
recently shown promising results by improving NASH his-
tology and the expression of inflammatory cytokines in
both obese foz/foz mice and in mice fed a MCD diet, as
well as reducing weight gain and normalizing plasma glu-
cose and insulin levels in a mouse model of diet‐induced
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obesity.69 Furthermore, IVA337 prevented and reversed
CCl4‐induced liver fibrosis more effectively than any of the
single agonists fenofibrate (PPARα), GW501516 (PPARδ)
and rosiglitazone (PPARγ).69 Currently, investigators are
recruiting patients with more than 10% intrahepatic triglyc-
erides for a phase 2 trial (ClinicalTrials.gov identifier:
NCT03459079), and patients with histologically proven
NASH for a phase 2b trial testing IVA337 (ClinicalTrials.-
gov identifier: NCT03008070). These results support the
use of dual and pan agonists as the future PPAR‐targeting
treatment in NAFLD, although their efficacy in humans
remains to be confirmed in randomized, controlled clinical
trials.
5 | CONCLUDING REMARKS
Despite the identification of PPARγ almost 25 years ago,
the search for new and more specific ways of targeting this
nuclear receptor continues and may prove valuable in
future treatment strategies for NAFLD and NASH patients.
PPARγ exerts distinct functions in the liver, and while
PPARγ activation in HSCs and macrophages seems benefi-
cial in protecting against NAFLD and NASH promotion,
the opposite is true for hepatocytes. In vitro studies have
discovered cell‐ and tissue‐specific post‐translational modi-
fications of PPARγ, suggesting that PPARγ‐mediated unde-
sirable side effects may be reduced through specific
treatment targets. An improved overall outcome could also
be achieved by targeting more than one PPAR subtype,
that is dual or pan agonists, hereby optimizing beneficial
effects. Thus, though NAFLD/NASH and associated hep-
atic fibrosis is the result of a complex and yet undisclosed
causal interaction between multiple factors, PPARs appear
to play a central role in the propagation of disease, with
PPARγ currently taking the lead as a pivotal factor in driv-
ing or diminishing hepatic damage. The ability to selec-
tively balance beneficial and undesirable effects will
determine their future therapeutic potential in NAFLD.
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